A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

Clinical trial NCT06326411 · RECRUITING

Trial details

NCT number: NCT06326411
Sponsor: Nested Therapeutics, Inc
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Oncology MEK Mutation RAF Gene Mutation Ras (KRAS or NRAS) Gene Mutation Melanoma NSCLC Glioma Solid Tumor, Adult MAPK Pathway Gene Mutation

Start date: 2024-04-09
Primary completion: 2028-11-01
Enrollment: 230

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.